Pegfilgrastim

Generic Name
Pegfilgrastim
Brand Names
Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
Drug Type
Biotech
Chemical Formula
-
CAS Number
208265-92-3
Unique Ingredient Identifier
3A58010674
Background

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...

Indication

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non­ myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...

Associated Conditions
Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
Associated Therapies
-
Clinical Trials
Related News

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

First Posted Date
2009-02-05
Last Posted Date
2024-04-03
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
334
Registration Number
NCT00837265

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

First Posted Date
2008-12-16
Last Posted Date
2016-10-24
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
39
Registration Number
NCT00808639
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Lahey Clinic, Burlington, Massachusetts, United States

🇺🇸

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 1 locations

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Not Applicable
Terminated
Conditions
Hematologic Malignancies
Interventions
Drug: Pegfilgrastim
First Posted Date
2008-06-04
Last Posted Date
2018-04-20
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
7
Registration Number
NCT00689884
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

First Posted Date
2008-05-05
Last Posted Date
2020-12-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
220
Registration Number
NCT00671658
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

First Posted Date
2008-03-11
Last Posted Date
2020-04-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
21
Registration Number
NCT00632827
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

First Posted Date
2007-11-07
Last Posted Date
2019-05-29
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
5
Registration Number
NCT00554463
Locations
🇺🇸

McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States

🇺🇸

Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States

🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 11 locations

Various G-CSF Regimens to Prevent Infection During Chemotherapy

First Posted Date
2007-09-27
Last Posted Date
2019-11-06
Lead Sponsor
Academisch Ziekenhuis Maastricht
Target Recruit Count
172
Registration Number
NCT00536081
Locations
🇳🇱

Maxima Medisch Centrum, Eindhoven, Netherlands

🇳🇱

Wilhelmina Ziekenhuis, Assen, Netherlands

🇳🇱

Groene Hart Ziekenhuis, Gouda, Netherlands

and more 18 locations

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

First Posted Date
2007-07-19
Last Posted Date
2016-06-09
Lead Sponsor
University of Miami
Target Recruit Count
22
Registration Number
NCT00503984
Locations
🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

First Posted Date
2007-07-11
Last Posted Date
2011-02-15
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
399
Registration Number
NCT00499018
Locations
🇮🇹

Istituto Vito Fazzi, Lecce, Italy

🇮🇹

Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy

🇮🇹

Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 71 locations

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

First Posted Date
2007-05-24
Last Posted Date
2020-10-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT00478361
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield, Springfield, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy